Abstract： Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare autoimmune disease that affects multiple systems. In recent years, the treatment of patients with EGPA has become more systematic and standardized. Biological agents, in particular, have demonstrated significant advantages in efficacy. In this review, we summarized the indications and side effects of biological agents in the treatment of EGPA, and reviewed the most recent EGPA treatment guidelines, in order to help clinicians provide more standardized management for EGPA patients.